ESTRO 2025 - Abstract Book

S2026

Clinical - Urology

ESTRO 2025

Conclusion: PET/CT-PSMA significantly influenced radiotherapy planning for PC patients with BCR after RP. It improved detection of pelvic-nodal and oligometastatic disease, leading to increased use of PSMA-guided SBRT, PRT, PBRT with dose escalation in PSMA-positive areas. Post-PSMA treatment approach resulted in favorable PSA biochemical responses.

Keywords: PET-PSMA, Prostate cancer, Biochemical recurrence

3033

Digital Poster Better biochemical free survival is obtained with extensive rather than directed radiotherapy for prostate cancer PET positive lymph nodes Andrei Fodor 1 , Chiara Brombin 2,3 , Laura Giannini 1 , Alessandro Nonis 2 , Chiara Lucrezia Deantoni 1 , Sara Broggi 4 , Miriam Torrisi 1 , Cesare Cozzarini 1 , Antonella Del Vecchio 4 , Claudio Fiorino 4 , Mariaclelia Stefania Di Serio 2,3 , Nadia Gisella Di Muzio 1,5 1 Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. 2 University Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy. 3 Psychology, Vita-Salute San Raffaele University, Milan, Italy. 4 Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, Italy. 5 Medicine, Vita-Salute San Raffaele University, Milan, Italy Purpose/Objective: There is no clear indication for the radiotherapy (RT) field extension for prostate cancer (PCa) patients presenting positron emission tomography (PET) positive (+) lymph-nodes (LN). Extended nodal radiotherapy (ENRT) determines